Haisco(SZ:002653) Zheng Quan Ri Bao·2025-10-13 13:35Group 1 - The core point of the article is that the company, Hai Si Ke, announced that its subsidiary, Shanghai Hai Si Sheng Nuo Pharmaceutical Technology Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the drug HSK55718, which is intended for clinical trial registration for domestic production [2] Group 2 - The drug HSK55718 is currently in the process of obtaining approval for clinical trials, indicating potential advancements in the company's product pipeline [2] - The acceptance of the application by the regulatory authority suggests a positive step towards the commercialization of HSK55718, which may enhance the company's market position [2] - This development reflects the company's ongoing efforts to expand its pharmaceutical offerings and engage in research and development activities [2]